Discover what healthcare professionals (HCPs) think about pharmaceutical products and their manufacturers, as it happens, through CREATION.co’s tracking updates. How are HCPs responding to drug launch news? How are HCPs talking about or engaging with the Top 50 pharma companies on social media? Each week, CREATION.co’s tracking updates bring you the latest insights from the conversation of HCPs across the globe discussing these topics and more.
The Top 50 Pharmaceutical Companies mentioned by HCPs on Twitter
| January Rank | December Rank | Company Name | Total Mentions | Account Mentions | Account Retweets |
|---|---|---|---|---|---|
| 1 | 1 | Pfizer | 16,888 | 956 | 51 |
| 2 | 2 | AstraZeneca | 1,804 | 246 | 11 |
| 3 | 3 | Johnson & Johnson | 1,763 | 461 | 45 |
| 4 | 5 | Regeneron | 703 | 27 | 3 |
| 5 | 4 | GSK | 587 | 146 | 31 |
| 6 | 7 | Abbott | 546 | 517 | 14 |
| 7 | 13 | Biogen | 536 | 331 | 2 |
| 8 | 6 | Roche | 387 | 110 | 20 |
| 9 | 9 | Novartis | 316 | 144 | 9 |
| 10 | 14 | Lilly | 282 | 80 | 3 |
| 11 | 8 | Merck & Co | 276 | 159 | 23 |
| 12 | 11 | Gilead Sciences | 211 | 18 | 6 |
| 13 | 15 | Sanofi | 180 | 77 | 18 |
| 14 | 12 | Bayer | 178 | 53 | 10 |
| 15 | 10 | Novo Nordisk | 174 | 142 | 9 |
| 16 | 22 | Takeda | 165 | 160 | 7 |
| 17 | 20 | Amgen | 104 | 80 | 9 |
| 18 | 17 | AbbVie | 80 | 48 | 6 |
| 19 | 24 | Boehringer Ingelheim | 77 | 53 | 22 |
| 20 | 18 | Otsuka | 68 | 3 | 0 |
| 21 | 26 | Fresenius | 64 | 48 | 20 |
| 22 | 16 | BMS | 51 | 36 | 2 |
| 23 | 21 | Chugai | 46 | 5 | 3 |
| 24 | 34 | Eisai | 44 | 17 | 2 |
| 25 | 32 | UCB | 39 | 26 | 4 |
| 26 | 28 | Merck KGaA | 38 | 33 | 7 |
| 27 | 19 | Teva | 35 | 15 | 10 |
| 28 | 35 | Servier | 30 | 10 | 4 |
| 29 | 31 | Ipsen | 27 | 14 | 2 |
| 30 | 29 | Daiichi Sankyo | 22 | 6 | 1 |
| 31 | 39 | Bausch | 22 | 1 | 0 |
| 32 | 23 | Mylan | 19 | 0 | 0 |
| 33 | 30 | Allergan | 18 | 1 | 0 |
| 34 | 25 | Vertex | 16 | 15 | 0 |
| 35 | 27 | Astellas | 14 | 7 | 1 |
| 36 | 37 | Sun | 14 | 8 | 1 |
| 37 | 40 | Menarini | 13 | 9 | 9 |
| 38 | 36 | CSL | 9 | 9 | 5 |
| 39 | 33 | Alexion | 9 | 3 | 0 |
| 40 | 38 | Grifols | 7 | 1 | 0 |
| 41 | 50 | Aurobindo | 3 | 0 | 0 |
| 42 | 42 | Mitsubishi Tanabe Pharma | 1 | 1 | 0 |
| 50 | 50 | Jiangsu Hengrui | 0 | 0 | 0 |
| 50 | 50 | Ono | 0 | 0 | 0 |
| 50 | 41 | Endo | 0 | 0 | 0 |
| 50 | 50 | Meiji | 0 | 0 | 0 |
| 50 | 50 | Yunnan Baiyao | 0 | 0 | 0 |
| 50 | 50 | Sino | 0 | 0 | 0 |
| 50 | 50 | Shanghai | 0 | 0 | 0 |
| 50 | 50 | Sumitomo Dainippon | 0 | 0 | 0 |
The latest insights from HCPs mentioning the Top 50 Pharmaceutical Companies
The five pharmaceutical companies that were mentioned the most by healthcare professionals (HCPs) on Twitter during January 2022 were Pfizer, AstraZeneca, Johnson & Johnson, Regeneron and GSK.
COVID-19 news, especially regarding vaccines, continued to drive conversations about the Top 50 Pharmaceutical companies in January. HCPs largely discussed the efficacy of different vaccines and booster doses. Specifically, HCPs talked positively about the mixing and matching of vaccines when getting their booster shots. This hasn’t always been the case; previous research showed HCP views changed over time with regards to mixing vaccinations. Pfizer received nine times as many mentions as the next company (AstraZeneca).
Science says you get higher antibodies when you mix and match booster shots.
Three of us in my family boosted our Pfizer with Moderna and have twice as many antibodies (3-4 months out) as the three who boosted Pfizer with Pfizer. pic.twitter.com/dIVGQkrQhM
— Dr. Victoria Dooley (@DrDooleyMD) January 15, 2022
The most shared links by HCPs were all regarding the efficacy of COVID-19 vaccines:
- A presentation by the CDC on COVID-19 vaccine safety updates in children and adolescents.
- A Journal article on the effectiveness of the Pfizer vaccine against Multisystem Inflammatory Syndrome in children aged 12-18.
- A Journal article comparing Moderna and Pfizer COVID-19 vaccines.
COVID-19 made up 55% of the conversations from HCPs about Top 50 Pharmaceutical companies. This was mostly impacted by the discussions about booster vaccines.
In January 2022, Regeneron ranked a spot higher into the fourth most talked about pharmaceutical company as HCPs continued to discuss their monoclonal antibodies’ ineffectiveness against the Omicron variant. US HCPs got political with 43% of posts that mentioned Regeneron also discussing a US governor’s role pushing the use of the monoclonal antibody treatments.
I’m impressed by @PressSec’s response and knowledge that there are different monoclonal antibodies and some work against #Omicron while some don’t. But that doesn’t stop @GovRonDeSantis from pushing MABs that don’t work on Omicron like Regeneron—who is coincidentally a big donor. https://t.co/8C39T45HPE
— Eric Feigl-Ding (@DrEricDing) January 25, 2022
CREATION.co continues to analyse online HCP conversation on a variety of topics including virtual congress, healthcare changes since the pandemic, product development and therapy area specific insights.
To stay up to date, you can sign up to CREATION.co’s monthly eJournal.
Methodology notes:
- In January 2022, CREATION Pinpoint® identified 23,774 healthcare professional (HCP) authored tweets from 9,032 individual HCPs mentioning a Top 50 Pharmaceutical company (according to revenue).
- Data for this research was analysed from the online Twitter conversations of HCPs in all languages mentioning a Top 50 Pharmaceutical company between January 1st and January 31st 2022.
- Unless otherwise specified, mentions of a company are not limited to its Twitter account(s).
- In some cases, a tweet may mention more than one company account (e.g. @abbottnews and @abbottglobal) – this only counts as one Company Mention and Account Mention.
- Johnson & Johnson was included as a whole, encompassing its pharmaceutical subsidiary, Janssen. In January 483 of these posts mentioned Janssen.
